¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"active site-directed irreversible inhibitor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • active exercise
    ´Éµ¿¿îµ¿
  • active gradient shielding
    ´Éµ¿°æ»çÂ÷Æó
  • active hyperemia
    ´Éµ¿ÃæÇ÷
  • active imagination
    Àû±Ø»ó»ó, Àû±Ø¸í»ó
  • active immunity
    ´Éµ¿¸é¿ª
  • active immunization
    ´Éµ¿¸é¿ªÈ­
  • active incorporative mode
    Àû±ØÇÔÀÔ¾ç½Ä
  • active marrow
    Ȱ¼º°ñ¼ö
  • active material
    Ȱ¼º¹°Áú, Ȱ¼ºÀç
  • active movement
    ´Éµ¿¿îµ¿
  • active negativism
    Àû±Ø°ÅºÎÁõ
  • active oxygen
    Ȱµ¿»ê¼Ò, Ȱ¼º»ê¼Ò
  • active phase
    Ȱ¼º±â
  • active placebo
    Ȱ¼º¼ÓÀÓ¾à
  • active prosthesis
    Ȱµ¿ÀÇÁö, ´Éµ¿ÀÇÁö
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • active exercise
    ´Éµ¿¿îµ¿
  • active hydrogen
    Ȱ¼º¼ö¼Ò
  • active hyperemia
    ´Éµ¿ÃæÇ÷
  • active imagination
    Àû±Ø»ó»ó, Àû±Ø¸í»ó
  • active immunity
    ´Éµ¿¸é¿ª
  • active immunization
    ´Éµ¿¸é¿ªÈ­
  • active marrow
    Ȱ¼º°ñ¼ö
  • active material
    Ȱ¼º¹°Áú
  • active movement
    ´Éµ¿¿îµ¿
  • active negativism
    Àû±Ø°ÅºÎÁõ
  • active oxygen
    Ȱµ¿»ê¼Ò, Ȱ¼º»ê¼Ò
  • active placebo
    ¾ç¼º¼ÓÀÓ¾à
  • active prosthesis
    Ȱµ¿ÀÇÁö, ´Éµ¿ÀÇÁö
  • active shielding
    ´Éµ¿°¡¸², ´Éµ¿Â÷Æó
  • active shimming
    ´Éµ¿º¸Á¤
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • active exercise
    ÀÚµ¿¿îµ¿(í»ÔÑê¡ÔÑ).
  • active exercise
    ÀÚµ¿¿îµ¿(í»ÔÑê¡ÔÑ).
  • active force generation test
    ±Ù·Â°Ë»ç
  • active glycine
    Ȱ¼º(üÀàõ)±Û¸®½Å.
  • active gradient shielding
    ´Éµ¿ °æ»ç Â÷Æó
  • active hydrogen
    Ȱ¼º¼ö¼Ò(¡­â©áÈ).
  • active imagination
    Àû±ØÀû »ó»ó
  • active immunity
    ´Éµ¿¸é¿ª(ÒöÔÑØóæ¹).
  • active immunization
    ´Éµ¿¸é¿ª(È­)(ÊÙÌ´).
  • active immunization
    ´Éµ¿¸é¿ª¹ý, ´Éµ¿¸é¿ªÁ¶Ä¡
  • active incorporative mode
    Àû±ØÀû ÇÔÀÔ ¾ç½Ä
  • active marrow
    Àû°ñ¼ö.
  • active material
    Ȱ¼º¹°Áú(üÀàõÚªòõ).
  • active movement
    ´Éµ¿¿îµ¿(ÒöÔÑê¡ÔÑ)
  • active negativism
    Àû±Ø¼º °ÅÀýÁõ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • active oxygen
    Ȱ¼º»ê¼Ò(üÀàõß«áÈ).
  • active shielding
    ´Éµ¿ Â÷Æó
  • active shimming
    ´Éµ¿ º¸Á¤
  • active site
    Ȱ¼ºÀÚ¸®.
  • active spot
    Ȱ¼ºÁ¡(üÀàõïÇ).
  • active tension
    ´Éµ¿Àå·Â(ÒöÔÑíåæ³)
  • active transport
    ´Éµ¿(Àû)¿î¹Ý(¡­îÜê¡Úæ), ´Éµ¿(Àû)¼ö¼Û(ÒöÔÑîÜâÃáê)
  • active treatment
    Á÷Á¢Ä¡·á, Àû±Ø¿ä¹ý(îÝпèþÛö).
  • active tuberculosis
    Ȱµ¿¼º °áÇÙ(Áõ)(üÀÔÑàõÌ¿ú·ñø).
  • artificial active immunity
    Àΰø´Éµ¿¸é¿ª.
  • assisted active exercise
    º¸Á¶´Éµ¿¿îµ¿.
  • assisted active exercise
    º¸Á¶´Éµ¿¿îµ¿.
  • cationic active agent
    ¾çÀÌ¿ÂȰ¼ºÁ¦(åÕ¡­üÀàõð¥).
  • chronic active hepatitis
    ¸¸¼ºÈ°µ¿¼º °£¿°(¡­ÊÜæú).
  • chronic active hepatitis
    ¸¸¼º Ȱµ¿¼º °£¿°
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • active amino acid
    Ȱ¼º(üÀàõ)¾Æ¹Ì³ë»ê (ß«)
  • active anaphylaxis
    Ȱ¼º(üÀàõ)¾Æ³ªÇʶô½Ã½º
  • active carbohydrate
    Ȱ¼º´çÁú (üÀàõÓØòõ)
  • active carbon
    Ȱ¼ºÅº (üÀàõ÷©)
  • active carbon dioxide
    Ȱ¼ºÀÌ»êȭź¼Ò (üÀàõì£ß«ûù÷©áÈ)
  • active center
    Ȱ¼ºÁß½É(üÀàõñéãý)
  • active concentration
    Ȱ¼º³óµµ(üÀàõÒØÓø)
  • active form
    Ȱ¼ºÇü(üÀàõû¡)
  • active formaldehyde
    Ȱ¼º(üÀàõ)Æ÷¸§¾Ëµ¥ÇÏÀ̵å
  • active formate
    Ȱ¼º(üÀàõ)Æ÷¸§»ê(ß«)
  • active formimino
    Ȱ¼º(üÀàõ) Æ÷¸§À̹̳ë
  • active fructose
    Ȱ¼º(üÀàõ)ÇÁ¶ôÅäÁî
  • active glycolaldehyde
    Ȱ¼º(üÀàõ)±Û¸®Äݾ˵¥ÇÏÀ̵å
  • active hydroxyethyl
    Ȱ¼º(üÀàõ)ÇÏÀ̵å·Ï½Ã¿¡Æ¿
  • active hydroxymethyl
    Ȱ¼º(üÀàõ)ÇÏÀ̵å·Ï½Ã¸ÞÆ¿
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
AFP Alpha(¥á) Feto-Protein [HP 1826, 1858, 1859, 2265]
  ; Oncofetal Antigens
 &nbs...
AVP   1) Active non apeptide(?)
  2) Arginine Vaso-Pressin
CAH   1) Chronic Active Hepatitis
  2) Congenital Adrenal Hyperplasia
RAIU Radio-Active Iodine Uptake
AAE active assistive exercise; acute allergic encephalitis; American Association of Endodontists; annulo...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
AR Active renin
AT Active tension
AI-CAH Autoimmune chronic active hepatitis
CAH Chronic Active Hepatitis
CAH-B Chronic active hepatitis B
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • active shimming
    ´Éµ¿ º¸Á¤
  • active state
    Ȱµ¿ »óÅÂ
    ±ÙÀ°ÀÌ ¼öÃàÇÒ ¶§, ¼öÃà¿ä¼Ò ÀÚü¿¡ ÀϾ°í ÀÖ´Â ¿ªÇÐÀû »óÅÂÀÌ´Ù. ±ÙÀ° ÀÚü¿¡ ź¼º¿ä¼Ò°¡ Á¸ÀçÇϹǷΠ´Ü¼øÇÑ ¼öÃà°î¼±ÀÇ ±â·ÏÀ¸·Î Ȱµ¿»óȲÀ» ¾Ë ¼ö ¾ø´Ù. ¼öÃà¿ä¼Ò´Â ±ÙÀ°ÀÌ ÀڱصǸé Áï½Ã Ȱµ¿»óŰ¡ µÇ°í, Á¦2, Á¦3ÀÇ ÀÚ±ØÀÌ °¡ÇØÁ®µµ ÀÌ È°µ¿»óÅ´ °­È­µÇÁö ¾Ê°í ´Ü¼øÈ÷ Áö¼Ó½Ã°£ÀÌ ¿¬ÀåµÉ »ÓÀÌ´Ù.
  • active transport
    ´Éµ¿ À̵¿
    È®»ê¿¡ ÀÇÇØ¼­°¡ ¾Æ´Ï¶ó ¿î¹Ýü¿¡ ÀÇÇØ ¿¡³ÊÁö¸¦ ¼ÒºñÇØ °¡¸ç ³óµµ¿¡ ¿ªÇàÇØ¼­ ¹°ÁúÀÌ À̵¿µÇ´Â Çö»ó.
  • active tuberculosis
    Ȱµ¿¼º °áÇÙ, Ȱµ¿¼º °áÇÙÁõ
    ȯÀÚ¿¡¼­ ±ÕÀÌ °ËÃâµÇ´Â »óÅ¿¡ ÀÖ´Â °áÇÙ.
  • chronic active hepatitis
    ¸¸¼º Ȱµ¿¼º °£¿°
  • coagualtion-active substance
    ÀÀ°í Ȱ¼º ¹°Áú
  • full active opening
    ´Éµ¿ °³±¸·®
  • multiple biologically active peptide fragment
    ´Ù¹ß¼º »ý¹°ÇÐÀû Ȱ¼º ÆéŸÀÌµå ºÐÀý
  • natural active immunity
    ÀÚ¿¬ ´Éµ¿ ¸é¿ª
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
proteinase inhibitor inducing factor See: PIIF.
(18 Nov 1997)
protein c inhibitor <chemical> A member of the serpin family of proteins that is found in plasma and urine. It is dependent on heparin and able to inhibit activated protein c, thrombin, kallikrein, and other serine proteinases.
Pharmacological action: serine proteinase inhibitors.
(12 Dec 1998)
protein synthesis inhibitor Compounds which inhibit the synthesis of proteins. They are usually antibiotics or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the the a site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins.
(12 Dec 1998)
proton pump inhibitor <pharmacology> A group of anti-ulcer medications which work by binding to H+/K+ ATPase, an enzyme which is found on the secretory surface of parietal cells. It thereby inhibits the final transport of hydrogen ions (via exchange with potasium) into the gastric lumen.
Examples of proton pump inhibitors include omeprazole and lansoprazole.
(27 Sep 1997)
HMG CoA reductase inhibitor Drugs, such as lovastatin and pravastatin, which interfere with the biosynthesis of cholesterol; used to treat hyperlipidemia.
(05 Mar 2000)
selective serotonin reuptake inhibitor <pharmacology> This is a class of drug that are used as antidepressants.
Functionally, they increase the levels of serotonin in the body. These drugs can be dangerous if they are mixed with other drugs such as other antidepressants, illicit drugs (LSD, cocaine, methamphetamine), some antihistamines (Seldane, Histmanal), some antibiotics, and calcium channel blockers.
Side effects include lethargy, confusion, flushing, sweating and muscle spasms. Overdose can cause damage to red blood cells, breathing problems and kidney damage.
Examples include: Prozac, Zoloft and Paxil.
Acronym: SSRI
(12 Jan 1998)
human a1-proteinase inhibitor A glycoprotein that is the major protease inhibitor of human serum, is synthesised in the liver, and is genetically polymorphic due to the presence of over 20 alleles; individuals appropriately homozygous are deficient in a1-trypsin and are predisposed to pulmonary emphysema and juvenile hepatic cirrhosis because of alterations in the amino acid and sialic acid components of the glycoprotein. A1-Antitrypsin also inhibits thrombin.
Synonym: a1-trypsin inhibitor, human a1-proteinase inhibitor.
(05 Mar 2000)
serine protease inhibitor A class of highly polymorphic inhibitors of trypsin, elastase, and certain other proteases synthesised by hepatocytes and macrophages
See: a1-antitrypsin.
Synonym: serpins.
(05 Mar 2000)
soybean trypsin inhibitor Single polypeptide (21 kD, 181 amino acids) that forms a stable, stoichiometric, enzymically inactive complex with trypsin.
(18 Nov 1997)
noncompetitive inhibitor <chemistry> Reversible inhibition of an enzyme by a compound that binds at a site other than the substrate binding site.
(18 Nov 1997)
inhibitor <chemistry, pharmacology> A molecule which represses or prevents another molecule from engaging in a reaction.
See: inhibition.
(09 Oct 1997)
inter-alpha-inhibitor <chemical> Inhibits bovine trypsin and chymotrypsin; complex formed with chymotrypsin less stable; alpha-glycoprotein; shap - serum-derived hyaluronan associated protein
Pharmacological action: serine proteinase inhibitors, trypsin inhibitors
Chemical name: trypsin inhibitor, inter-alpha-
Synonym: inter-alpha-trypsin inhibitor, protein pi, inter-alpha-trypsin inhibitor, heavy chain, shap protein
(05 Dec 1998)
ovulation inhibitor A compound that inhibits ovulation; often found in oral contraceptives.
(05 Mar 2000)
tissue-inhibitor of metalloproteinase-1 <chemical> A member of the family of tissue inhibitor of metalloproteinases. It is a n-glycosylated protein, molecular weight 28 kD, produced by a vast range of cell types and found in a variety of tissues and body fluids. It has been shown to suppress metastasis and inhibit tumour invasion in vitro.
Pharmacological action: antineoplastic agent, protease inhibitors.
(12 Dec 1998)
tissue inhibitor-of metalloproteinase-2 <chemical> A member of the family of tissue inhibitor of metalloproteinases. It is a 21 kD nonglycosylated protein found in tissue fluid and is secreted as a complex with progelatinase a by human fibroblast and uncomplexed from alveolar macrophages. An overexpression of timp-2 has been shown to inhibit invasive and metastatic activity of tumour cells and decrease tumour growth in vivo.
Pharmacological action: antineoplastic agent, protease inhibitors.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á